Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
CONCLUSIONS: Currently, there is no evidence from randomised clinical trials that people with intermediate-stage hepatocellular carcinoma would benefit from systemic chemotherapy with sorafenib either alone or when transarterial chemoembolisation was used as a cointervention (very low quality evidence). We need high-quality randomised clinical trials designed to measure differences in clinically important outcomes (e.g. all-cause mortality or health-related quality of life).
PMID: 28281295 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS Tags: Cochrane Database Syst Rev Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Children | Cirrhosis | Clinical Trials | Databases & Libraries | General Medicine | Hepatocellular Carcinoma | Hospital Management | Hypertension | International Medicine & Public Health | Liver | Liver Cancer | Liver Transplant | Science | Study | Transplants | Urology & Nephrology | WHO